{"name":"Guangzhou JOYO Pharma Co., Ltd","slug":"guangzhou-joyo-pharma-co-ltd","ticker":"","exchange":"","domain":"guangzhoujoyopharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"JYP0322 tablets","genericName":"JYP0322 tablets","slug":"jyp0322-tablets","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Cross-over to JYP0322","genericName":"Cross-over to JYP0322","slug":"cross-over-to-jyp0322","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"JYP0015","genericName":"JYP0015","slug":"jyp0015","indication":"Other","status":"phase_2"},{"name":"Singletine","genericName":"Singletine","slug":"singletine","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Intravenous Glucocorticoids","genericName":"Intravenous Glucocorticoids","slug":"intravenous-glucocorticoids","indication":"Treatment of acute lymphoblastic leukemia","status":"phase_2"}]}],"pipeline":[{"name":"JYP0322 tablets","genericName":"JYP0322 tablets","slug":"jyp0322-tablets","phase":"phase_3","mechanism":"JYP0322 tablets are a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Cross-over to JYP0322","genericName":"Cross-over to JYP0322","slug":"cross-over-to-jyp0322","phase":"phase_3","mechanism":"JYP0322 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Intravenous Glucocorticoids","genericName":"Intravenous Glucocorticoids","slug":"intravenous-glucocorticoids","phase":"phase_2","mechanism":"Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the cytoplasm.","indications":["Treatment of acute lymphoblastic leukemia"],"catalyst":""},{"name":"JYP0015","genericName":"JYP0015","slug":"jyp0015","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Singletine","genericName":"Singletine","slug":"singletine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNVFpieWVrTlg2eTRIZTVmUmZ6MEhYTlZZMHg4cHU4ME1pUWp0SjlkRHBJcVA0S1l3VjdBeXl1Wk8wNmZLYVJzSWxuY1YxRWg0c05Ec3BhdlNoZkNsdnR4MEFmUGdWUHZIV0lBMlJFbW4tZWQ4OVVubFhWbHloSnpjb0tqN3RtZ0pTNmxXM2RGQ01VUFIxMG04QTMycHEwaERjTkR0UGlrdHEydkJlemcwUlBUalEtaWlxTjVzZkJ4LUc1czNiSTIyM2VjMi1rRm8xZU5FWTZTaUhtT0N0UUVwd2xNUWVjY2xYVVlCYUwtbkUzSzB5dTVqTnQ2SDFYcG5sNkZLN09KU2xURG8tRHpod0EyVGE?oc=5","date":"2026-03-19","type":"trial","source":"Barchart.com","summary":"Pulmonary Fibrosis Clinical Trial Analysis 2026: 110+ Companies Advancing 140+ Therapies with Breakthrough Clinical Progress, analyses DelveInsight - Barchart.com","headline":"Pulmonary Fibrosis Clinical Trial Analysis 2026: 110+ Companies Advancing 140+ Therapies with Breakthrough Clinical Prog","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxOdm90RzFBMHJuOEwya29VbGhyb2dLMTRscWFmSzdjN0F2LVpGMENiYVE5MXZRbXIxdVNJMU84VXdQY04yREFZbkE4QmVjdlkxTVZEZzdSSF9xYzF1SGl4aDBRV2N3OW9qNU5uNzFRa09LZUJkWWVrQlJ0VHVPR0dnMFRmMDBQOF82ZTlKak94WUhCelhNeFFIa0ZkdlhzUHl4c3VEUlotWUxiMmxnNndhQUY2QVQ4TWxMeTRycTFIbFFqVlpMcHg3b0IwUE9Ya19hSmUwaElxaGdNWDNDRk5CVUxzb0N3R3p5dXQ1c21sanYzYXhWSmpJenkwUGxqUHRMTlpDMy1JYl9KV3B2dTZtU29kdzg4LXNaLXNWRkdGemZoa19pQTQ5aWlNbE50MmZwMFhfdlduZ3VlZVZ1Qk1WaV9VcVBLal9JaWN5U2VwMFdVLUl0?oc=5","date":"2026-02-26","type":"regulatory","source":"Barchart.com","summary":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics ","headline":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOb2FpNnlvQ2NMX0ZSTnZkdGtFUXhFUzhyRXA4SjJQcF9uOHZRaWJDZ1hDUnZ0T0pLWmthYWRmM2NGTVNDZkFOQnZPbFlhY0lNUnJmNkpnYll3eERNOW8wVS1VMFV2QnE5bWMzZDBFcGduUUpqaDBpZGtSNlE1SDVDRTMxNENyMFJud3F0S3pyUi1rMHZhZ1JhUHNtc1VScWZoZkszc0lMYVFOaWhpUk5QMVhtbl92VU9WWlJnR2VwSnp5elhiV1hENHVXV0FpemhUa29jd0JxUGJqWnVFcTZ2dnAxWDQ4LTN4T3pyZ0xIcWtJdFk3dFVqaEp2cng2b0lSOTd0YTVQNGFXMzZteTA0N3VpbDg0U3dDT2J2QVliNGdPUldNa0Zndi1mRzZ3a3h1dHc?oc=5","date":"2026-02-09","type":"trial","source":"GlobeNewswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3FBTE9tSFhFOG1MMTJyZDNuSFc4aHdYY1paY0RYN0pGdXdKZF9KMG9XdWJoS3d6QnFjTVF3QUhBTjZYcEV6TEdrUUREcjF0Sjk0TTIwbzF3UDN3bk9BNmpPSGh1bEhRMmJRTUxJM0s0T3lKeEFTcVFGSVVqbTVoT1EzbzhpdVhzOUtldW8wTmtUdw?oc=5","date":"2025-05-20","type":"trial","source":"Yahoo Finance","summary":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - Yahoo Finance","headline":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9xMExKS0dZZWNNeEtPUV9iUi1BZW92VkxkUUVjQmt1STJCejV5a0NBa3YwOS1CYXJvamFSZUh1dUJWbnVnWHBkRjJ0bm5tdXluZEhnT3RtSDY4Yy1MZEwxT1otRUxmQ2doVS1BZ2otSjBWWWh0NFY3YTE0aw?oc=5","date":"2025-05-14","type":"trial","source":"Oncology Pipeline","summary":"Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5NOUt0bHgwbzFueHFTTWF0WC1Zb2o4Q2ZxVExLQXpPdE9ES25vWnZZQl9jb24tcFpRdEwyUzQ1VHN2ZnZWdFAzSEFqbGtrXzBSQVJ5OGxYLWZYaUlkVU15VWc3MGx2dkhsX2VGNlppejRpLVU?oc=5","date":"2024-05-17","type":"trial","source":"Oncology Pipeline","summary":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBXUGV6S3BrUW9wSUk5eGJJQ3k2ekppVktnN3NITzc2UTVYV3UtWFN6cWFCc3hTRzA5ZDRaejd5Z1pQOG9RbTl1bjNMUG9EdzRJcElDVmw4SENGTGJR?oc=5","date":"2021-08-20","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Erasca, Inc. (ERAS) Company Profile & Facts - Yahoo! Finance Canada","headline":"Erasca, Inc. (ERAS) Company Profile & Facts - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}